Immunotherapy with SLPI over-expressing mammary tumor cells decreases tumor growth.

AMIANO NO; REITERI RM; COSTA MJ; TATEOSIAN N; CHULUYAN HE

CANCER IMMUNOLOGY IMMUNOTHERAPY

SPRINGER

Lugar: Berlin; Año: 2011 vol. 60 p. 895 - 900

0340-7004

Abstract We have demonstrated previously that theinoculation of murine mammary tumor cells geneticallymodiWed to express high levels of secretory leukocyteprotease inhibitor (2C1) do not develop tumors in immunocompetentmice and these cells are more prone to apoptosisthan control cells. The aim of the present study was to evaluatethe role of the adaptive immune response in the lack oftumor growth of 2C1 cells and the possibility of using thesecells for immunotherapy. The s.c. administration of mocktransfected F3II cells induces tumor in BALB/c and Nudemice. However, the inoculation of 2C1 cells developstumor in Nude but not in BALB/c mice. The inoculation ofmock transfected F3II cells to 2C1 immunized BALB/cmice by repeated administration of 2C1 cells (once a weekfor 3 weeks) developed signiWcantly smaller tumors thanthose observed in non-immunized mice. Remarkably, survivalof tumor-bearing immunized mice was higher thannon-immunized animals. Herein, we demonstrate that animmunotherapy with SLPI over-expressing non-irradiatedtumor cells which do not develop tumor in immunocompetentmice, partially restrain the tumor growth induced byF3II cells and increase the survival of the mice.